Treatment of Hepatitis C, Hepatitis A, and Hepatitis B
Hepatitis C Treatment
For chronic hepatitis C, use pangenotypic direct-acting antiviral (DAA) regimens: sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8-12 weeks depending on cirrhosis status and treatment history. These regimens achieve >95% sustained virologic response (SVR) rates across all genotypes and have revolutionized HCV therapy 1, 2.
Treatment Algorithm by Genotype and Cirrhosis Status:
Genotype 1a, 1b, 2,4,5, or 6:
- Without cirrhosis (treatment-naïve or experienced): Sofosbuvir/velpatasvir 12 weeks OR glecaprevir/pibrentasvir 8 weeks 1
- With compensated cirrhosis (treatment-naïve): Sofosbuvir/velpatasvir 12 weeks OR glecaprevir/pibrentasvir 8 weeks 1
- With compensated cirrhosis (treatment-experienced): Sofosbuvir/velpatasvir 12 weeks OR glecaprevir/pibrentasvir 12 weeks 1
Genotype 2 specific recommendations:
- Treatment-naïve without cirrhosis: Glecaprevir/pibrentasvir 8 weeks (SVR 99%) OR sofosbuvir/velpatasvir 12 weeks (SVR 100%) 3
- Treatment-naïve with cirrhosis: Glecaprevir/pibrentasvir 12 weeks OR sofosbuvir/velpatasvir 12 weeks 3
- Treatment-experienced: Same durations as treatment-naïve 3
Genotype 3 (requires special attention):
- Without cirrhosis (treatment-naïve): Sofosbuvir/velpatasvir 12 weeks OR glecaprevir/pibrentasvir 8 weeks 1
- Without cirrhosis (treatment-experienced): Sofosbuvir/velpatasvir 12 weeks OR glecaprevir/pibrentasvir 12 weeks 1
- With compensated cirrhosis (treatment-naïve): Sofosbuvir/velpatasvir + weight-based ribavirin 12 weeks OR sofosbuvir/velpatasvir/voxilaprevir 12 weeks OR glecaprevir/pibrentasvir 12 weeks 1
- With compensated cirrhosis (treatment-experienced): Sofosbuvir/velpatasvir + ribavirin 12 weeks OR sofosbuvir/velpatasvir/voxilaprevir 12 weeks 1
Critical Considerations:
Genotype 3 with cirrhosis requires ribavirin addition because SVR rates drop significantly without it—from 97% to 84% in cirrhotic patients treated with daclatasvir/sofosbuvir alone 3. Adding ribavirin or extending treatment improves SVR to 93% 3.
Acute hepatitis C should be treated immediately rather than waiting for chronic infection. Treatment of acute HCV is cost-effective ($19,991 per QALY) and becomes cost-saving in patients at risk of transmission 4. This represents a paradigm shift from older guidelines.
Common Pitfalls:
- Do not defer treatment in patients with ongoing substance use—they achieve comparable SVR rates to other populations 2
- Do not withhold treatment based on fibrosis stage—universal treatment is recommended for all adults with chronic HCV except those with short life expectancy 2
- Genotype testing remains useful to optimize outcomes, though pangenotypic regimens have simplified therapy 1
Hepatitis A Treatment
Acute hepatitis A is self-limited and requires only supportive care—no antiviral therapy exists or is needed. Management focuses on symptom relief and monitoring for rare complications 5.
Management Approach:
- Outpatient management for most cases with adequate oral intake
- High-calorie diet, bedrest if symptomatic
- Avoid hepatotoxic medications and alcohol
- Hospitalization indicated for:
- Inability to maintain oral intake due to nausea/vomiting requiring IV hydration
- Any mental status changes suggesting fulminant hepatic failure 5
Prevention:
- Post-exposure prophylaxis is available and should be administered when indicated 6
- Vaccination recommended for all persons with chronic liver disease including those with hepatitis B or C 2
Fulminant hepatic failure from hepatitis A is rare but can require liver transplantation 5. Monitor closely for signs of hepatic decompensation.
Hepatitis B Treatment
For chronic hepatitis B, use nucleos(t)ide analogues (NAs): entecavir or tenofovir are optimal first-line agents, typically requiring long-term or lifelong therapy. These drugs suppress HBV replication, normalize liver enzymes, and prevent progression to cirrhosis 7, 8.
Treatment Indications (Traditional Guidelines):
Traditional guidelines restricted treatment to patients with:
- High HBV DNA levels
- Elevated liver enzymes (ALT)
- Evidence of hepatic fibrosis
However, recent evidence supports broader treatment access. The pathological processes induced by HBV are active even in individuals outside traditional treatment criteria 7. WHO and Chinese guidelines have expanded treatment eligibility, though a "test-and-treat" approach may be superior 7.
Optimal Treatment Agents:
- Entecavir or tenofovir are preferred over lamivudine due to higher barrier to resistance 8
- Treatment duration is generally lifelong with NAs 8
- "Functional cure" (HBsAg loss) is rare with current NAs 9
Monitoring Requirements:
- HBsAg, HBeAg, anti-HBe status
- Quantitative HBsAg and HBV DNA levels
- Liver disease staging (biopsy, elastography, or serum fibrosis markers) 8
- HCC surveillance in cirrhotic patients and HBsAg inactive carriers using ultrasound, MSCT, or MRI 8
Special Considerations:
HBV reactivation risk during HCV treatment: Screen all HCV patients for HBsAg before starting DAA therapy. Those positive for HBsAg require HBV DNA monitoring during and after HCV treatment, with consideration for anti-HBV therapy 2.
Decompensated cirrhosis: NAs (entecavir, tenofovir) can be used safely in decompensated cirrhotics, unlike interferon which is contraindicated 10. Liver transplantation offers >80% 5-year survival 10.
Prevention:
- Universal neonatal vaccination is the current policy 8
- Screen high-risk populations for HBsAg, anti-HBc, and anti-HBs antibodies 8
Future Directions:
Novel therapeutic strategies aim for selective HBsAg suppression combined with immunostimulation to achieve functional cure more frequently 9.
Key Differences in Approach:
- Hepatitis C: Curative with short-course DAA therapy (8-12 weeks), treat all patients
- Hepatitis A: Self-limited, supportive care only, no antiviral therapy
- Hepatitis B: Suppressive therapy with NAs, typically lifelong, expanding treatment criteria recommended